Provectus Biopharmaceuticals, Inc. has released a manuscript preprint describing how investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprietary small molecule rose bengal disodium (RBD), in combination with gemcitabine may enhance the chemotherapy’s efficacy against pancreatic tumors. Chemotherapy regimens that include gemcitabine are the standard of care for the treatment of pancreatic cancer. The injection of PV-10 into mouse pancreatic tumors caused lesion-specific ablation, The combination of PV-10 and systemic administration of gemcitabine caused lesion-specific ablation and delayed the growth of untreated distal tumors, The combination was markedly more successful in immunogenic tumors that express the neoantigen ovalbumin, suggesting PV-10 and gemcitabine enhanced the immune clearance of tumors, and The regression of tumors in mice that received PV-10 in combination with gemcitabine was associated with the depletion of myeloid-derived suppressor cells (MDSCs) and increases in damage associated molecular patterns (DAMPs) high-mobility group box 1 (HMGB1), S100A8, and interleukin-1a.